Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials.

In patients with advanced cancer and a prognosis <2 years, the addition of statins to standard anti-cancer therapy does not appear to improve overall survival or progression-free survival. Future research should assess if cancer patients with better prognosis benefit from longer-term statin therapy.